Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00988858 · ClinicalTrials.gov registry record · Phase 2
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00988858 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 55 participants.
The verdict
NCT00988858, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the efficacy and safety of LY2603618 in combination with pemetrexed and any side effects that might be associated with it along with determining the effects of LY2603618 in combination with pemetrexed in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC).
Interventions
- DRUG Pemetrexed
- DRUG LY2603618
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2009-11 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00988858
The ClinicalTrials.gov registry entry for NCT00988858 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pemetrexed is the first listed.
NCT00988858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00988858 about?
NCT00988858 is a clinical study titled "A Study of Advanced or Metastatic Non-small Cell Lung Cancer". The primary purpose of this study is to evaluate the efficacy and safety of LY2603618 in combination with pemetrexed and any side effects that might be associated with it along with determining the effects of LY2603618 in combination with pemetrexed in participants with advanced or metastatic Non-sm...
What is the current status of trial NCT00988858?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2009-11. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00988858?
The interventions under investigation include: Pemetrexed (DRUG), LY2603618 (DRUG).
Who is sponsoring clinical trial NCT00988858?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.